AIDS 2026: Exciting news from this global HIV conference
1 October 2026. Related: News.
Simon Collins, HIV i-Base
These links are to reports from the AIDS 2026 conference held from 26-30 July 2026 in Rio de Janeiro.
Review of plenary lecture by leading researcher Raphael Landovitz on the PrEP efficacy, recent UK guidelines and the importance of politics to enable global access.
All proceedings and resources from this essential conference are now online open-access.
For the first time in many years, IAS has enabled free open access to the opening ceremony and closing sessions as live webcasts and YouTube videos. These moving and important sessions are free for everyone to be able to watch even if they were not able to be a delegate.
Cure-related research show bNAbs could be as important in chronic HIV as in acute infection with early ART. New biomarkers could predict responders, driven by reduced reservoir diversity rather than reservoir size.
Review on ART pipelines including two oral weekly combinations, access to long-acting injectables, bNAbs and more.
This new report includes data to help track progress to global HIV goals for 2030 – including impact of funding changes in 2025.
Even before the AIDS 2026 conference opens, the online programme shows some of the expected highlights.
This review covers new drugs and ART strategies, the global funding crisis, cure-related research, key populations including transgender people and community concerns including chemsex.
Lenacapavir PURPOSE-1 and -2 studies show continued high efficacy as PrEP.